# US 2016/0060206 A1 · Fatty alcohol esters of hydroxycarboxylic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0060206 A1
- Document ID: US20160060206A1
- Status: Published application
- Kind: A1
- Application number: 14/939,422
- Filed: 2015-11-12
- Published: 2016-03-03
- Earliest claimed: 2010-09-17
- Assignees: Chemsmart, LLC
- Applicants: Chemsmart, LLC
- Inventors: Joseph P. St. Laurent; Scott A. Goodrich; Gerald S. Jones, JR.
- Web page: https://patentgrep.com/patent/US20160060206A1

## CPC

- C07C 69/68: Lactic acid esters
- C08G 65/3322: {acyclic}
- C12P 7/62: Carboxylic acid esters
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- C07B 2200/07: Optical isomers
- Y02P 20/52: using catalysts, e.g. selective catalysts
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, methods of making compounds of formula (I) and their use in the treatment and/or prevention of diseases and disorders.

## Claims

### Claim 1

A composition configured for topical administration, comprising a compound of formula (I):
wherein
R1 is a C12 alkyl;
n is an integer from 4 to 10; and
R2 is hydrogen, alkyl, aryl, heteroaryl, or heterocyclyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein R2 is alkyl.

### Claim 3 (depends on 2)

The composition of claim 2, wherein R2 is C1-4 alkyl.

### Claim 4 (depends on 1)

The composition of claim 1, wherein R2 is aryl.

### Claim 5 (depends on 2)

The composition of claim 2, wherein R2 is aralkyl.

### Claim 6 (depends on 1)

The composition of claim 1, wherein when R2 is not hydrogen, the compound of formula (I) is a racemic mixture of a compound of formula (I).

### Claim 7 (depends on 1)

The composition of claim 1, wherein when R2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the R stereoisomer.

### Claim 8 (depends on 7)

The composition of claim 7, wherein when R2 is not hydrogen, the compounds of formula (I) is at least 50% enantiomeric excess of the R stereoisomer.

### Claim 9 (depends on 8)

The composition of claim 8, wherein when R2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the R stereoisomer.

### Claim 10 (depends on 9)

The composition of claim 9, wherein when R2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the R stereoisomer.

### Claim 11 (depends on 10)

The composition of claim 10, wherein when R2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the R stereoisomer.

### Claim 12 (depends on 11)

The composition of claim 11, wherein when R2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the R stereoisomer.

### Claim 13 (depends on 12)

The composition of claim 12, wherein when R2 is not hydrogen, the compound of formula (I) is least 97% enantiomeric excess of the R stereoisomer.

### Claim 14 (depends on 13)

The composition of claim 13, wherein when R2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the R stereoisomer.

### Claim 15 (depends on 1)

The composition of claim 1, wherein when R2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the S stereoisomer.

### Claim 16 (depends on 1)

The composition of claim 1, wherein when R2 is not hydrogen, the compound of formula (I) is at least 50% enantiomeric excess of the S stereoisomer.

### Claim 17 (depends on 16)

The composition of claim 16, wherein when R2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the S stereoisomer.

### Claim 18 (depends on 17)

The composition of claim 17, wherein when R2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the S stereoisomer.

### Claim 19 (depends on 18)

The composition of claim 18, wherein when R2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the S stereoisomer.

### Claim 20 (depends on 19)

The composition of claim 19, wherein when R2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the S stereoisomer.

### Claim 21 (depends on 20)

The composition of claim 20, wherein when R2 is not hydrogen, the compound of formula (I) is at least 97% enantiomeric excess of the S stereoisomer.

### Claim 22 (depends on 21)

The composition of claim 21, wherein when R2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the S stereoisomer.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the compound of formula (I) is represented by the following formula:
wherein n is 4.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the compound of formula (I) is represented by the following formula:
wherein n is 4.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the compound of formula (I) is represented by the following formula:
wherein n is 4.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the composition is a gel.

### Claim 27

A composition configured for topical administration, comprising a compound of formula (I):
wherein
R1 is a C8-35 alkyl;
n is an integer from 4 to 10; and
R2 is hydrogen, alkyl, aryl, heteroaryl, or heterocyclyl;
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

The composition of claim 27, wherein R1 is a C8-25 alkyl group.

### Claim 29 (depends on 28)

The composition of claim 28, wherein R1 is a C10-20 alkyl group.

### Claim 30 (depends on 29)

The composition of claim 29, wherein R1 is a C10-15 alkyl group.

### Claim 31 (depends on 30)

The composition of claim 30, wherein R1 is a C12 alkyl group.

### Claim 32 (depends on 27)

The composition of claim 27, wherein R2 is alkyl.

### Claim 33 (depends on 32)

The composition of claim 32, wherein R2 is C1-4 alkyl.

### Claim 34 (depends on 27)

The composition of claim 27, wherein R2 is aryl.

### Claim 35 (depends on 32)

The composition of claim 32, wherein R2 is aralkyl.

### Claim 36 (depends on 27)

The composition of claim 27, wherein when R2 is not hydrogen, the compound of formula (I) is a racemic mixture of a compound of formula (I).

### Claim 37 (depends on 27)

The composition of claim 27, wherein when R2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the R stereoisomer.

### Claim 38 (depends on 27)

The composition of claim 27, wherein when R2 is not hydrogen, the compounds of formula (I) is at least 50% enantiomeric excess of the R stereoisomer.

### Claim 39 (depends on 38)

The composition of claim 38, wherein when R2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the R stereoisomer.

### Claim 40 (depends on 39)

The composition of claim 39, wherein when R2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the R stereoisomer.

### Claim 41 (depends on 40)

The composition of claim 40, wherein when R2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the R stereoisomer.

### Claim 42 (depends on 41)

The composition of claim 41, wherein when R2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the R stereoisomer.

### Claim 43 (depends on 42)

The composition of claim 42, wherein when R2 is not hydrogen, the compound of formula (I) is least 97% enantiomeric excess of the R stereoisomer.

### Claim 44 (depends on 43)

The composition of claim 43, wherein when R2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the R stereoisomer.

### Claim 45 (depends on 27)

The composition of claim 27, wherein when R2 is not hydrogen, the compound of formula (I) is at least 10% enantiomeric excess of the S stereoisomer.

### Claim 46 (depends on 27)

The composition of claim 27, wherein when R2 is not hydrogen, the compound of formula (I) is at least 50% enantiomeric excess of the S stereoisomer.

### Claim 47 (depends on 46)

The composition of claim 46, wherein when R2 is not hydrogen, the compound of formula (I) is at least 75% enantiomeric excess of the S stereoisomer.

### Claim 48 (depends on 47)

The composition of claim 47, wherein when R2 is not hydrogen, the compound of formula (I) is at least 85% enantiomeric excess of the S stereoisomer.

### Claim 49 (depends on 48)

The composition of claim 48, wherein when R2 is not hydrogen, the compound of formula (I) is at least 90% enantiomeric excess of the S stereoisomer.

### Claim 50 (depends on 49)

The composition of claim 49, wherein when R2 is not hydrogen, the compound of formula (I) is at least 95% enantiomeric excess of the S stereoisomer.

### Claim 51 (depends on 50)

The composition of claim 50, wherein when R2 is not hydrogen, the compound of formula (I) is at least 97% enantiomeric excess of the S stereoisomer.

### Claim 52 (depends on 51)

The composition of claim 51, wherein when R2 is not hydrogen, the compound of formula (I) is at least 99% enantiomeric excess of the S stereoisomer.

### Claim 53 (depends on 27)

The composition of claim 27, wherein the compound of formula (I) is represented by the following formula:
wherein n is 4.

### Claim 54 (depends on 27)

The composition of claim 27, wherein the compound of formula (I) is represented by the following formula:
wherein n is 4.

### Claim 55 (depends on 27)

The composition of claim 27, wherein the compound of formula (I) is represented by the following formula:
wherein n is 4.

### Claim 56 (depends on 27)

The composition of claim 27, wherein the composition is a gel.